Spaulding Clinical Announces Hiring of Medical Director Neal Collins, M.D.

WEST BEND, Wis.--(BUSINESS WIRE)-- Spaulding Clinical Research announced today that it has hired Neal Collins, M.D., as medical director, effective February 1, 2021. In this role, Dr. Collins will be leading medical staff and overseeing Phase I clinical research studies while based in Spaulding’s West Bend, Wis., clinical pharmacology unit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005130/en/

Neal Collins, M.D., medical director at Spaulding Clinical (Photo: Business Wire)

Prior to Spaulding Clinical, Dr. Collins ran his own consultancy, working with select clients and projects in medical and clinical affairs and business development. Previously, he was senior medical director, immuno-oncology, global medical affairs at EMD Serono, responsible for global strategic and commercial activity. Before that, he served in senior positions at Merck, AstraZeneca and Pfizer for 17 years.

“I am excited to welcome Dr. Collins to Spaulding Clinical,” said CEO Cassandra Erato. “As a leader in Phase I-IV clinical trials oversight as well as regulatory alignment and strategy, his wealth of experience in both global and U.S. markets makes him a valuable addition. His broad therapeutic expertise — spanning oncology, internal medicine, primary care, infectious disease, vaccines, women’s health and endocrinology — will be especially valuable during this time of growth for Spaulding.”

A full-service, state-of-the-art Phase I clinical testing facility, Spaulding Clinical specializes in cardiac safety testing and provides the highest-quality data to not only save biopharmaceutical clients time and money, but also uncover risks early in drug development. From our industry-leading experts to our highly trained nurses and research staff, every employee is focused and committed to ensuring clean, high-quality data for Phase I trials and beyond.

About Spaulding Clinical Research

Spaulding Clinical opened in 2008 and was built upon fully electronic data and integrated, purposefully engineered systems for conducting Phase I trials. Spaulding runs a 200-bed facility in West Bend, Wis., and conducts and analyzes first-in-human, clinical proof-of-concept, cardiovascular safety (TQT, concentration effect) and NDA-enabling clinical pharmacology studies. Spaulding Clinical provides expertise on study design, medical writing, clinical data management, biostatistics and PK/PD analysis. Learn more at spauldingclinical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005130/en/